IPO market abuzz with biotech offerings
IPO market abuzz with biotech offerings
The buzz is biotech — at least as far as initial public offerings are concerned in the fourth quarter.
IPO market abuzz with biotech offerings
The buzz is biotech — at least as far as initial public offerings are concerned in the fourth quarter.
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.

Leave a Reply
Want to join the discussion?Feel free to contribute!